Skip to main content

Xenleta Side Effects

Generic name: lefamulin

Medically reviewed by Last updated on Dec 1, 2023.

Note: This document contains side effect information about lefamulin. Some dosage forms listed on this page may not apply to the brand name Xenleta.

Applies to lefamulin: oral tablet. Other dosage forms:

Serious side effects of Xenleta

Along with its needed effects, lefamulin (the active ingredient contained in Xenleta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lefamulin:

Less common

Incidence not known

Other side effects of Xenleta

Some side effects of lefamulin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to lefamulin: intravenous solution, oral tablet.


Very common (10% or more): Diarrhea (up to 12%)

Common (1% to 10%): Nausea, vomiting

Frequency not reported: Abdominal pain, constipation, dyspepsia, epigastric discomfort, erosive gastritis, Clostridium difficile-associated diarrhea, C difficile colitis, oropharyngeal candidiasis[Ref]


Common (1% to 10%): Administration site reactions (included infusion site pain, infusion site phlebitis, injection site reaction)[Ref]


Common (1% to 10%): Hepatic enzyme elevation (included increased ALT, increased AST, increased liver function test)

Frequency not reported: Increased GGT[Ref]


Common (1% to 10%): Hypokalemia[Ref]


Common (1% to 10%): Insomnia

Frequency not reported: Anxiety[Ref]

Nervous system

Common (1% to 10%): Headache

Frequency not reported: Somnolence[Ref]


Common (1% to 10%): Death within 28 days

Frequency not reported: Increased alkaline phosphatase[Ref]

Death within 28 days occurred in 1.2% of patients treated with this drug and 1.1% of patients treated with moxifloxacin.[Ref]


Frequency not reported: Atrial fibrillation, palpitations, prolonged QT on ECG[Ref]


Frequency not reported: Vulvovaginal candidiasis, urinary retention[Ref]


Frequency not reported: Anemia, thrombocytopenia[Ref]


Frequency not reported: Increased creatine phosphokinase[Ref]


1. Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.